Meeting slides
Interactive presentation

Immunopathogenesis of SLE

Interactive presentation

Additional Q&A From Live Syposium Featuring Dr. Richard Furie

Suggested Readings

European League Against Rheumatism (EULAR) 2020 Annual Meeting Abstracts.

June 3-6, 2020. Virtual.

American College of Rheumatology (ACR) Annual Meeting Abstracts.

November 5-9, 2020. Virtual.

Treat-to-target in systemic lupus erythematosus: recommendations from an international task force.

van Vollenhoven RF, et al. Ann Rheum Dis. 2014;73(6):958-967.

Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial.

Furie RA, et al. Lancet Rheumatol. 2019;1(4):e208-e219.

Trial of anifrolumab in active systemic lupus erythematosus.

Morand EF, et al. N Engl J Med. 2020;382(3):211-221.

Anifrolumab, an anti–interferon-α receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus.

Furie R, et al. Arthritis Rheumatol. 2017;69(2):376-386.

A phase 3, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.

Furie R, et al. Arthritis Rheum. 2011;63(12):3918-3930.

Two-year, randomized, controlled trial of belimumab in lupus nephritis.

Furie RA, et al. N Engl J Med. 2020;383(12):1117-1128.

Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab.

Morand EF, et al. Ann Rheum Dis. 2018;77(5):706-713.

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.

Navarra SV, et al. Lancet. 2011;377(9767):721-731.

AURORA phase 3 study demonstrates voclosporin statistical superiority over standard of care in lupus nephritis.

Arriens C, et al. Ann Rheum Dis. 2020;79(suppl 1):172-173.

B-cell depletion and response in a randomized, controlled trial of obinutuzumab for proliferative lupus nephritis.

Furie R, et al. Lupus Sci Med. 2020;7(suppl 1):A27-A28.

Comprehensive efficacy of anifrolumab across organ domains in patients with active SLE: pooled data from 2 phase 3 trials.

Morand E, et al. Arthritis Rheumatol. 2020;72(suppl 10).

Flare reduction and oral corticosteroid taper in patients with active SLE treated with anifrolumab in 2 phase 3 trials.

Furie R, et al. Arthritis Rheumatol. 2020;72(suppl 10).

Related activities
2.00 CME/CE

What's New in Systemic Lupus Erythematosus?

Unlocking Novel Paths to Patient Care

Faculty: Richard A. Furie, MD; Elena M. Massarotti, MD; Eric Morand, MBBS (Hons), PhD, FRACP
Release: 12/31/2020
Expiration: 12/31/2021